• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S ADR (NQ: GMAB )

    21.18 -0.48 (-2.22%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,462,424
    Open 21.75
    Bid (Size) 21.00 (15)
    Ask (Size) 21.83 (1)
    Prev. Close 21.66
    Today's Range 21.17 - 21.82
    52wk Range 21.17 - 32.89
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Closer Look at 10 Analyst Recommendations For Genmab
    Via Benzinga
    Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
    From Genmab A/S
    Via Business Wire

    Performance

    YTD
    -34.04%
    -34.04%
    1 Month
    -8.63%
    -8.63%
    3 Month
    -22.16%
    -22.16%
    6 Month
    -28.57%
    -28.57%
    1 Year
    -33.21%
    -33.21%

    More News

    Read More
    Preview: Genmab's Earnings
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Via Chartmill
    When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    Via Chartmill
    12 Analysts Have This To Say About Genmab
    Via Benzinga
    NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
    Via Chartmill
    NASDAQ:GMAB is an undervalued gem with solid fundamentals.
    Via Chartmill
    NASDAQ:GMAB, a growth stock which is not overvalued.
    Via Chartmill
    Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
    Via Chartmill
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
    Via Chartmill
    Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
    From Genmab A/S
    Via Business Wire
    Expert Ratings For Genmab
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Via Chartmill
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    Via Chartmill
    Decoding 10 Analyst Evaluations For Genmab
    Via Benzinga
    TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Genmab Announces Changes to its Executive Committee
    From Genmab A/S
    Via Business Wire
    Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
    Via Chartmill
    On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
    Via Benzinga
    GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
    Via Benzinga
    Exposures COVID-19
    While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.